Intercept Pharmaceuticals Inc logo

Intercept Pharmaceuticals Inc

$ 18.40 +0.03 (+0.16%) 10:08 PM EST
P/E:
3.21
P/B:
7.08
Market Cap:
$ 762.08M
Enterprise V:
$ 603.53M
Volume:
458.10K
Avg Vol (2M):
805.86K
Also Trade In:
Volume:
458.10K
Market Cap $:
762.08M
PE Ratio:
3.21
Avg Vol (2-Month):
805.86K
Enterprise Value $:
603.53M
PB Ratio:
7.08

Business Description

Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Name Current Vs Industry Vs History
Cash-To-Debt 1.48
Equity-to-Asset 0.19
Debt-to-Equity 3.09
Debt-to-EBITDA -3.07
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.5
Distress
Grey
Safe
Beneish M-Score -0.06
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 81.46
9-Day RSI 75.65
14-Day RSI 70.18
6-1 Month Momentum % -19.93
12-1 Month Momentum % -19.6

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.46
Quick Ratio 2.46
Cash Ratio 2.22
Days Sales Outstanding 34.53
Days Payable 1459.9

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 0.1